Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Letter to the Editor: Reconsidering fibrinolytic assessment and hemostatic management in liver transplantation.
Journal: Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
Published: November 06, 2025
Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of Tenosynovial Giant Cell Tumor (TGCT).
Journal: Bioorganic & medicinal chemistry letters
Published: June 08, 2022
Discovery of acyl ureas as highly selective small molecule CSF1R kinase inhibitors.
Journal: Bioorganic & medicinal chemistry letters
Published: June 08, 2022
Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by Macrophages.
Journal: Molecular cancer therapeutics
Published: April 29, 2021
A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer.
Journal: Molecular cancer therapeutics
Published: July 09, 2019
Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants.
Journal: Cancer cell
Published: November 09, 2018
The Selective Tie2 Inhibitor Rebastinib Blocks Recruitment and Function of Tie2Hi Macrophages in Breast Cancer and Pancreatic Neuroendocrine Tumors.
Journal: Molecular cancer therapeutics
Published: March 17, 2017
Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells.
Journal: Journal of medicinal chemistry
Published: May 13, 2015
Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2.
Journal: Molecular cancer therapeutics
Published: January 02, 2015
Effective inhibition of c-MET-mediated signaling, growth and migration of ovarian cancer cells is influenced by the ovarian tissue microenvironment.
Journal: Oncogene
Published: May 19, 2013
Showing 1-11 of 11
Last Updated: 09/26/2026